Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000469403 | SCV000542000 | likely benign | Neurofibromatosis, type 1 | 2024-10-07 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002313154 | SCV000663200 | uncertain significance | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2024-07-08 | criteria provided, single submitter | clinical testing | The p.A804P variant (also known as c.2410G>C) is located in coding exon 21 of the NF1 gene. The alanine at codon 804 is replaced by proline, an amino acid with highly similar properties. This change occurs in the first base pair of coding exon 21. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Gene |
RCV000681141 | SCV000808599 | uncertain significance | not provided | 2024-10-09 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; In silico analysis indicates that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 25486365) |
Genome- |
RCV000469403 | SCV002562041 | uncertain significance | Neurofibromatosis, type 1 | 2022-03-15 | criteria provided, single submitter | clinical testing | |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000681141 | SCV005624540 | uncertain significance | not provided | 2024-04-30 | criteria provided, single submitter | clinical testing |